港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

维立志博-B

58.000

0.000

成交量：- -

成交额：- -

市值：115.42亿

市盈率：-28.88

高：58.000

开：58.000

低：58.000

收：58.000

52周最高：83.600

52周最低：51.600

股本：1.99亿

香港流通股本：1.53亿

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(LYR):-2.008

净资产收益率：--

总资产收益率：--

市净率：100.64

市盈率(LYR):-28.88

市销率: - -

数据加载中...

总览公司新闻资讯公告

维立志博-B(09887.HK)涨超3%

每日经济新闻

港股异动 | 维立志博-B(09887)涨超3% 5项血液肿瘤领域研究成果于2025 ASH年会公布

CNS专题1：抗抑郁新靶点国内有哪些映射？

维立志博-B11月04日主力净流入203.2万元散户资金抛售

口头报告！维立志博5项血液肿瘤领域研究成果重磅登陆2025 ASH年会

维立志博生物科技

维立志博-B(09887)：1项LBL-034临床研究获选在第67届ASH年会首日作第一个口头报告

【券商聚焦】信达证券首予维立志博(09887)“买入”评级指ADC平台未来可期

维立志博-B10月31日主力净流出37.7万元散户资金买入

刚刚 20%涨停！重磅消息引爆！

港股创新药调整期真的来了？维立志博董事长康小强：不会将注意力集中于“追风”

每日经济新闻

港股生物科技板块集体走弱

每日经济新闻

超百亿美元大单却带不动股价创新药BD催化剂失灵？

港股创新药的调整期真的来了？对话维立志博董事长康小强：不会把注意力集中在“追风”上

每日经济新闻

维立志博-B(09887)：LBL-024于一线治疗胆道癌II期试验的首例患者用药

维立志博-B10月23日主力净流出277.1万元散户资金买入

超42亿美元！今日5款国产创新药掀起出海热潮

生物药大时代

维立志博-B药品LBL-047成功出海获3800万美元首付款潜在收益高达10亿美元

最高10亿美元！和美国一家生物科技公司签了个“独家授权协议”！

维立志博-B(09887)就LBL-047与DIANTHUS签订全球独家许可协议

Nanjing Leads Biolabs - 将获得高达3800万美元的预付款和潜在的近期里程碑支付，临床开发潜在总额可达10亿美元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/09887/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":58,"timestamp":1763427605004,"preClose":58,"halted":0,"volume":0,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"开市前","change":0,"latestTime":"11-18 09:01:00","open":58,"high":58,"low":58,"amount":0,"amplitude":0,"askPrice":60.5,"askSize":1000,"bidPrice":57.3,"bidSize":6300,"shortable":3,"etf":0,"ttmEps":-1.858667,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":1,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":58,"openAndCloseTimeList":[[1763429400000,1763438400000],[1763442000000,1763452800000]],"volumeRatio":0,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"--","roe":"--","lyrEps":-2.008042,"shares":199000000,"dividePrice":0,"high":58,"amplitude":0,"preClose":58,"low":58,"week52Low":51.6,"pbRate":"100.64","week52High":83.6,"institutionHeld":0,"latestPrice":58,"committee":0.726027,"eps":-2.008042,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.858667,"open":58,"prevYearClose":35,"fiveDayClose":59.35,"twentyDayClose":65,"sixtyDayClose":70},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1762531200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2025-11-14","current":-31.205159,"percent":0.896104,"low":-50.052922,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"high":-34.030535,"avg":-41.326136,"sd":3.17833,"marketCap":11734616200},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200}],"updateTime":1763410600146},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2581716839","title":"维立志博-B(09887.HK)涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581716839","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581716839?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 11:32","pubTimestamp":1762313547,"startTime":"0","endTime":"0","summary":"每经AI快讯，维立志博-B(09887.HK)涨超3%，截至发稿，涨3.49%，报57.9港元，成交额2020.56万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511053555689937.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511053555689937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2581171560","title":"港股异动 | 维立志博-B(09887)涨超3% 5项血液肿瘤领域研究成果于2025 ASH年会公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2581171560","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581171560?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 11:20","pubTimestamp":1762312846,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B(09887)涨超3%，截至发稿，涨3.49%，报57.9港元，成交额2020.56万港元。消息面上，11月4日，维立志博-B发布公告，内容有关5篇研究摘要入选美国血液学会以于其第67届年会上展示。公司欣然提供有关其在研创新药 LBL-034及LBL-076的进一步详情，该等药物的多份研究摘要已被第67届ASH年会收录。其中，1项LBL-034临床研究获选在大会首日作第一个口头报告，展示LBL-034对复发╱难治性多发性骨髓瘤患者的最新疗效及安全性数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ASH","LU2463526074.USD","09887","BK4109","BK1161"],"gpt_icon":0},{"id":"2581590745","title":"CNS专题1：抗抑郁新靶点 国内有哪些映射？","url":"https://stock-news.laohu8.com/highlight/detail?id=2581590745","media":"华福证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581590745?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 00:00","pubTimestamp":1762272000,"startTime":"0","endTime":"0","summary":"创新药CNS系列专题：抗抑郁市场潜力巨大，众多新靶点即将迎来催化：抑郁市场空间庞大：根据2021年全球疾病负担研究，全球抑郁症发病数超3.5亿人，其中国内抑郁症患者超过9000万人，患者疾病负担巨大。新一代抗抑郁药的研发需在“快速起效”与“长期安全”间寻求平衡。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110515274694f05d0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110515274694f05d0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","LU2778985437.USD","BK1574","LU0417516902.SGD","02696","09887","IE00B543WZ88.USD","LU2488822045.USD","LU0348735423.USD","LU1961090484.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU0540923850.HKD","LU0561508036.HKD","01801","LU0348827113.USD","06978","LU0348766576.USD","BK1161","LU0634319403.HKD","LU0417516571.SGD","LU0348784397.USD","LU0417516738.SGD","LU2399975544.HKD","LU0348783233.USD","LU1794554557.SGD","LU1720050803.USD","02617","LU2476274720.SGD","LU0348767384.USD","01167","LU0348825331.USD","LU2476274308.USD"],"gpt_icon":0},{"id":"2580738376","title":"维立志博-B11月04日主力净流入203.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2580738376","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580738376?lang=zh_cn&edition=fundamental","pubTime":"2025-11-04 16:15","pubTimestamp":1762244135,"startTime":"0","endTime":"0","summary":"11月04日, 维立志博-B股价涨0.99%，报收55.95元，成交金额3193.8万元，换手率0.37%，振幅6.77%，量比0.64。维立志博-B今日主力资金净流入203.2万元，上一交易日主力净流出70.1万元。该股近5个交易日下跌6.04%，主力资金累计净流入1266.1万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入522.0万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511041618379752f6ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511041618379752f6ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2580520338","title":"口头报告！维立志博5项血液肿瘤领域研究成果重磅登陆2025 ASH年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2580520338","media":"维立志博生物科技","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580520338?lang=zh_cn&edition=fundamental","pubTime":"2025-11-04 08:46","pubTimestamp":1762217211,"startTime":"0","endTime":"0","summary":"最新的疗效和安全性数据将在ASH大会首日的首个口头报告专场，排在第一位进行汇报。临床前研究数据显示，LBL-076具有显著的抗肿瘤活性。维立志博首席医学官蔡胜利博士表示维立志博多项研究成果集中入选2025 ASH，以卓越的科研实力和创新成果，再次向全球学术界展示了公司在肿瘤免疫治疗领域的深厚积淀与领先地位。在多种移植有不同抗原表达水平MM肿瘤细胞的小鼠模型中，LBL-076均显示了显著的抗肿瘤活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104085552a48648b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104085552a48648b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2580622162","title":"维立志博-B(09887)：1项LBL-034临床研究获选在第67届ASH年会首日作第一个口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2580622162","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580622162?lang=zh_cn&edition=fundamental","pubTime":"2025-11-04 06:37","pubTimestamp":1762209451,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，内容有关5篇研究摘要入选美国血液学会以于其第67届年会上展示。公司欣然提供有关其在研创新药 LBL-034及LBL-076的进一步详情，该等药物的多份研究摘要已被第67届ASH年会收录。其中，1项LBL-034临床研究获选在大会首日作第一个口头报告，展示LBL-034对复发╱难治性多发性骨髓瘤患者的最新疗效及安全性数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4109","LU2463526074.USD","09887","BK1161","ASH"],"gpt_icon":0},{"id":"2580501002","title":"【券商聚焦】信达证券首予维立志博(09887)“买入”评级 指ADC平台未来可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2580501002","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580501002?lang=zh_cn&edition=fundamental","pubTime":"2025-11-03 13:18","pubTimestamp":1762147106,"startTime":"0","endTime":"0","summary":"金吾财讯 | 信达证券研报指出，维立志博 是国内稀缺的同时具备IO2.0+ADC2.0平台的Biotech，在IO联合ADC的大背景下，公司构建的新一代++成为其核心竞争力，基于三大技术平台全面布局 IO2.0、TCE、ADC 三大业界公认的肿瘤治疗前沿技术方向，全方位、多手段攻克肿瘤治疗难题。LBL-024 联合化疗一线治疗肺外神经内分泌癌、一线治疗小细胞肺癌均表现出了“Bestin-Class”竞争力，显著优于现有 SOC。LBL-024 单药治疗有望填补肺外神经内分泌癌末线治疗的空白。ADC平台未来可期。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1968896","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","601059","09887"],"gpt_icon":0},{"id":"2579461869","title":"维立志博-B10月31日主力净流出37.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2579461869","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579461869?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 16:15","pubTimestamp":1761898509,"startTime":"0","endTime":"0","summary":"10月31日, 维立志博-B股价跌5.79%，报收53.70元，成交金额4422.6万元，换手率0.54%，振幅9.47%，量比0.88。维立志博-B今日主力资金净流出37.7万元，上一交易日主力净流入346.0万元。该股近5个交易日下跌14.35%，主力资金累计净流出176.8万元；近20日主力资金累计净流入1614.8万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103116155194e71716&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103116155194e71716&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2579432799","title":"刚刚 20%涨停！重磅消息 引爆！","url":"https://stock-news.laohu8.com/highlight/detail?id=2579432799","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579432799?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 14:55","pubTimestamp":1761893740,"startTime":"0","endTime":"0","summary":"今日，A股、港股创新药概念股全线爆发，三生国健、舒泰神强势录得20%涨停。消息面上，10月30日，2025年国家医保谈判在北京开启。今年国谈在延续医保目录常规调整机制的基础上，首次正式引入“商保创新药目录”机制。根据国家医保局8月28日公告，2025年基本药品目录调整有535个药品通用名通过形式审查。5年内获批上市的新通用名药品，或治疗罕见病的独家药品可申报商保创新药目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031151209a6d84f76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031151209a6d84f76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","09887","BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2579126321","title":"港股创新药调整期真的来了？维立志博董事长康小强：不会将注意力集中于“追风”","url":"https://stock-news.laohu8.com/highlight/detail?id=2579126321","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579126321?lang=zh_cn&edition=fundamental","pubTime":"2025-10-30 22:34","pubTimestamp":1761834886,"startTime":"0","endTime":"0","summary":"今年国庆中秋假期前后，Biotech（生物科技公司）再次在港交所排起了长龙，而错峰递表的维立志博（HK09887，股价57.00港元，市值113.37亿港元）赶在7月完成了公司的“上市礼”。7月25日，当维立志博创始人康小强敲响铜锣，中国“TCE（T细胞衔接器）第一股”就此诞生。在业内，TCE远没有ADC（抗体偶联药物）的名气大。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510303550786512.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510303550786512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09887","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2579150721","title":"港股生物科技板块集体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=2579150721","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579150721?lang=zh_cn&edition=fundamental","pubTime":"2025-10-30 10:08","pubTimestamp":1761790123,"startTime":"0","endTime":"0","summary":"每经AI快讯，10月30日，港股生物科技板块集体走弱，荃信生物-B、维立志博-B跌超10%，荣昌生物、君实生物、药明生物纷纷下挫。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510303549808587.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510303549808587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02269","LU0039217434.USD","09887","LU0326950275.SGD","LU0708995583.HKD","LU1969619763.USD","IE00B0JY6N72.USD","LU0181495838.USD","LU0979878070.USD","LU0320764599.SGD","LU0456827905.SGD","LU0823426480.USD","AI","LU0327786744.USD","SG9999002463.SGD","LU1720050803.USD","LU0307460666.USD","02509","LU0516422952.EUR","LU0043850808.USD","LU2039709279.SGD","BK1141","09995","LU0516423174.USD","LU0359202008.SGD","BK4528","BK1589","BK4588","SG9999002562.SGD","LU3063872942.SGD","BK1161","LU0052750758.USD","LU0572944931.SGD","LU0819121731.USD","LU1794554557.SGD","BK1610","LU1688375341.USD","BK4551","BK1521","BK4543","LU1242518857.USD","LU0417516902.SGD","LU0516422440.USD","LU0456846285.SGD","LU0516422366.SGD","BK1576","LU0348825331.USD","LU0516423091.SGD","BK4023","LU0140636845.USD"],"gpt_icon":0},{"id":"2579768169","title":"超百亿美元大单却带不动股价 创新药BD催化剂失灵？","url":"https://stock-news.laohu8.com/highlight/detail?id=2579768169","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579768169?lang=zh_cn&edition=fundamental","pubTime":"2025-10-29 18:02","pubTimestamp":1761732120,"startTime":"0","endTime":"0","summary":"如今，即便收获了金额百亿美元以上的超“大单”，创新药企业的股价仍旧低迷。股价快速上涨往往伴随关键的消息催化剂。Choice数据显示，2025年上半年，市值达到百亿港元规模的港股上市公司中，仅有3家创新药企的营业收入出现下滑，其余8家企业的营业收入均出现增长。中邮证券分析师盛丽华判断，近期创新药板块持续调整，一方面消化前期涨幅，另一方面BD催化剂较少，博弈情绪退坡。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029180752a47b96ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029180752a47b96ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2242644610.SGD","06978","LU2097828714.EUR","LU2097828557.USD","LU0502904849.HKD","LU1969619763.USD","BK1583","03692","LU2097828631.EUR","LU2488822045.USD","BK1574","09887","BK1161","LU2097828474.EUR","BK1589","LU2097828805.USD","01801","LU0455707207.USD","LU2328871848.SGD"],"gpt_icon":1},{"id":"2578950471","title":"港股创新药的调整期真的来了？对话维立志博董事长康小强：不会把注意力集中在“追风”上","url":"https://stock-news.laohu8.com/highlight/detail?id=2578950471","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578950471?lang=zh_cn&edition=fundamental","pubTime":"2025-10-28 21:27","pubTimestamp":1761658072,"startTime":"0","endTime":"0","summary":"国庆中秋假期前后，Biotech（生物科技公司）再次在港交所排起了长龙，而错峰递表的维立志博（09887.HK）赶在3个月前完成了公司的“上市礼”。7月25日，当维立志博创始人康小强敲响铜锣，中国“TCE（T细胞衔接器）第一股”就此诞生。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510283547259438.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510283547259438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1574","BK1161","09887"],"gpt_icon":0},{"id":"2578614963","title":"维立志博-B(09887)：LBL-024于一线治疗胆道癌II期试验的首例患者用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2578614963","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578614963?lang=zh_cn&edition=fundamental","pubTime":"2025-10-27 18:11","pubTimestamp":1761559909,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，评价奥帕替苏米单抗用于一线治疗胆道癌的II期临床试验首例患者已成功用药，标志着该核心产品适应症拓展高效推进。LBL-024是一种同时靶向PD-L1与4-1BB的双特异性抗体，为针对肺外神经内分泌癌的全球首款达到注册临床阶段的靶向4-1BB受体的疗法。LBL-024亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1360491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09887"],"gpt_icon":1},{"id":"2577531442","title":"维立志博-B10月23日主力净流出277.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2577531442","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577531442?lang=zh_cn&edition=fundamental","pubTime":"2025-10-23 16:16","pubTimestamp":1761207365,"startTime":"0","endTime":"0","summary":"10月23日, 维立志博-B股价跌2.56%，报收62.70元，成交金额4090.7万元，换手率0.43%，振幅6.68%，量比1.23。维立志博-B今日主力资金净流出277.1万元，上一交易日主力净流入130.1万元。该股近5个交易日下跌5.28%，主力资金累计净流出178.9万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入3852.9万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023162318a6c99ca0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023162318a6c99ca0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2576700164","title":"超42亿美元！今日5款国产创新药掀起出海热潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2576700164","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576700164?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 11:08","pubTimestamp":1760670502,"startTime":"0","endTime":"0","summary":"根据公告，Visara将在协议生效后的30个工作日内向AskGene Pharma支付700万美元的一次性、不可退还的首付款。目前，LBL-047已获美国新药临床试验许可及中国IND受理。该交易总金额最高可达10亿美元。许可人将获得8,000万美元首付款，并有资格根据该产品开发、注册审批和商业化进展收取最高14.5亿美元里程碑付款，以及未来潜在产品销售的分级特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017131410a6be3dd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017131410a6be3dd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03692","BK1574","09887","06978","BK1161"],"gpt_icon":0},{"id":"2576995709","title":"维立志博-B药品LBL-047成功出海 获3800万美元首付款 潜在收益高达10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576995709","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576995709?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 10:28","pubTimestamp":1760668126,"startTime":"0","endTime":"0","summary":"维立志博-B（09887）发布公告，公司于2025年10月16日与DianthusTherapeutics,Inc.签订全球独家许可协议，双方将共同推进临床前资产及新型抗BDCA2-TACI双特异性融合蛋白LBL-047的开发。LBL-047已获得美国新药临床试验（IND）许可及中国内地IND受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510173537019885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09887","BK1161"],"gpt_icon":1},{"id":"2576195700","title":"最高10亿美元！和美国一家生物科技公司签了个“独家授权协议”！","url":"https://stock-news.laohu8.com/highlight/detail?id=2576195700","media":"企业上市","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576195700?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 10:24","pubTimestamp":1760667892,"startTime":"0","endTime":"0","summary":"核心事件：南京维立志博生物科技公司在2025年10月16日，和美国一家叫Dianthus的生物科技公司签了个“独家授权协议”。维立志博能得到什么：首付款和近期里程碑款：最高3800万美元。其中包括2000万美元的“签字费”，2025年第四季度再付500万美元，以及最高1300万美元的近期研发进展奖金。未来潜在巨额奖金：如果这款药后续的临床开发、审批和商业化都成功了，维立志博最高还能拿到10亿美元的里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017113537a4645d5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017113537a4645d5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2575374928","title":"维立志博-B(09887)就LBL-047与DIANTHUS签订全球独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2575374928","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575374928?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 20:55","pubTimestamp":1760619343,"startTime":"0","endTime":"0","summary":"本公司认为签订全球独家许可协议将加强本集团推进创新候选药物进入临床阶段以解决自身免疫疾病的承诺，并符合本公司及其股东的整体最佳利益。LBL-047以BAFF/APRIL和BDCA2为靶点，旨在同时抑制pDC的活性以及B细胞及浆细胞的分化及激活。LBL-047通过Fc区改造延长半衰期，可降低给药频次，提高患者依从性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)就LBL-047与DIANTHUS签订全球独家许可协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"1187782282","title":"Nanjing Leads Biolabs - 将获得高达3800万美元的预付款和潜在的近期里程碑支付，临床开发潜在总额可达10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187782282","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187782282?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 20:51","pubTimestamp":1760619069,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs - 将获得高达3800万美元的预付款和潜在的近期里程碑支付，临床开发潜在总额可达10亿美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":2,"totalSize":151,"code":"91000000","status":"200"}]}}